Total Payments
$196,559
2024 Payments
$3,496
Companies
41
Transactions
1,012
Medicare Patients
4,280
Medicare Billing
$1.2M
Payment Breakdown by Category
Other$131,863 (67.1%)
Food & Beverage$29,710 (15.1%)
Consulting$17,617 (9.0%)
Travel$15,656 (8.0%)
Education$1,712 (0.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $104,738 | 60 | 53.3% |
| Food and Beverage | $29,710 | 843 | 15.1% |
| Honoraria | $21,125 | 14 | 10.7% |
| Consulting Fee | $17,617 | 13 | 9.0% |
| Travel and Lodging | $15,656 | 67 | 8.0% |
| Compensation for serving as faculty or as a speaker for a medical education program | $6,000 | 2 | 3.1% |
| Education | $1,712 | 13 | 0.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Melinta Therapeutics, LLC | $47,014 | 99 | $0 (2023) |
| Merck Sharp & Dohme LLC | $36,279 | 163 | $0 (2024) |
| The Medicines Company | $27,680 | 56 | $0 (2018) |
| Cumberland Pharmaceuticals, Inc. | $21,606 | 55 | $0 (2024) |
| Astellas Pharma US Inc | $13,975 | 45 | $0 (2024) |
| Ferring Pharmaceuticals Inc. | $12,203 | 24 | $0 (2024) |
| GRT US Holding, Inc. | $9,407 | 45 | $0 (2022) |
| Theravance Biopharma, Inc. | $7,369 | 32 | $0 (2018) |
| CIPLA USA INC. | $7,099 | 20 | $0 (2022) |
| Insmed, Inc. | $4,618 | 55 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,496 | 129 | ViiV Healthcare Company ($845.51) |
| 2023 | $35,533 | 164 | Melinta Therapeutics, LLC ($21,059) |
| 2022 | $23,903 | 126 | Melinta Therapeutics, LLC ($12,498) |
| 2021 | $13,851 | 127 | Cumberland Pharmaceuticals, Inc. ($6,352) |
| 2020 | $17,169 | 114 | CIPLA USA INC. ($5,277) |
| 2019 | $27,135 | 107 | Merck Sharp & Dohme Corporation ($9,154) |
| 2018 | $27,347 | 107 | Merck Sharp & Dohme Corporation ($12,834) |
| 2017 | $48,124 | 138 | The Medicines Company ($27,584) |
All Payment Transactions
1,012 individual payment records from CMS Open Payments — Page 1 of 41
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | ABIOMED | Impella (Device) | Food and Beverage | Cash or cash equivalent | $40.73 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/19/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $20.77 | General |
| Category: Respiratory | ||||||
| 12/19/2024 | ABBVIE INC. | AVYCAZ (Drug), TEFLARO, DALVANCE | Food and Beverage | In-kind items and services | $9.89 | General |
| Category: ANTI-INFECTIVE | ||||||
| 12/19/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $6.75 | General |
| Category: ANTIBIOTIC | ||||||
| 12/18/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $19.53 | General |
| Category: HIV | ||||||
| 12/18/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $17.79 | General |
| Category: HIV | ||||||
| 12/10/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $29.04 | General |
| Category: HIV | ||||||
| 12/09/2024 | ABBVIE INC. | DALVANCE (Drug), AVYCAZ, TEFLARO | Food and Beverage | In-kind items and services | $24.10 | General |
| Category: ANTI-INFECTIVE | ||||||
| 12/05/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $13.05 | General |
| Category: HIV | ||||||
| 11/26/2024 | ABBVIE INC. | TEFLARO (Drug), DALVANCE | Food and Beverage | In-kind items and services | $19.49 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/26/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $6.42 | General |
| Category: Respiratory | ||||||
| 11/26/2024 | ABBVIE INC. | TEFLARO (Drug), DALVANCE | Food and Beverage | In-kind items and services | $1.59 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/21/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $22.05 | General |
| Category: ANTIBIOTIC | ||||||
| 11/21/2024 | ViiV Healthcare Company | APRETUDE (Biological) | Food and Beverage | In-kind items and services | $13.91 | General |
| Category: HIV | ||||||
| 11/20/2024 | Theratechnologies Inc. | EGRIFTA (Drug), TROGARZO | Food and Beverage | In-kind items and services | $31.98 | General |
| Category: HIV | ||||||
| 11/19/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $21.66 | General |
| Category: HIV | ||||||
| 11/19/2024 | ABBVIE INC. | AVYCAZ (Drug), TEFLARO, DALVANCE | Food and Beverage | In-kind items and services | $8.89 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/18/2024 | ABIOMED | Impella (Device) | Food and Beverage | Cash or cash equivalent | $34.54 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/15/2024 | ViiV Healthcare Company | APRETUDE (Biological) | Food and Beverage | In-kind items and services | $15.31 | General |
| Category: HIV | ||||||
| 11/14/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $29.81 | General |
| Category: HIV | ||||||
| 11/12/2024 | ABBVIE INC. | AVYCAZ (Drug), TEFLARO, DALVANCE | Food and Beverage | In-kind items and services | $9.65 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/07/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $30.76 | General |
| Category: Infectious Diseases | ||||||
| 11/07/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $7.83 | General |
| Category: Respiratory | ||||||
| 11/05/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $8.64 | General |
| Category: ANTIBIOTIC | ||||||
| 10/31/2024 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Food and Beverage | In-kind items and services | $20.10 | General |
| Category: GASTROENTEROLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 986 | 257,228 | $1.3M | $251,644 |
| 2022 | 11 | 1,089 | 272,700 | $1.4M | $280,767 |
| 2021 | 15 | 972 | 399,756 | $1.5M | $261,455 |
| 2020 | 13 | 1,233 | 545,188 | $2.1M | $409,569 |
Total Patients
4,280
Total Services
1,474,872
Medicare Billing
$1.2M
Procedure Codes
49
All Medicare Procedures & Services
49 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 284 | 888 | $186,480 | $81,333 | 43.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 157 | 563 | $157,640 | $50,677 | 32.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 319 | 369 | $151,290 | $49,074 | 32.4% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 38 | 624 | $151,576 | $32,040 | 21.1% |
| J0878 | Injection, daptomycin, 1 mg | Office | 2023 | 21 | 252,000 | $477,225 | $11,143 | 2.3% |
| 96374 | Injection of drug or substance into vein | Office | 2023 | 17 | 355 | $65,455 | $10,611 | 16.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 80 | 80 | $31,709 | $10,297 | 32.5% |
| J1335 | Injection, ertapenem sodium, 500 mg | Office | 2023 | 16 | 571 | $57,711 | $5,711 | 9.9% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2023 | 14 | 1,121 | $2,436 | $443.31 | 18.2% |
| J7050 | Infusion, normal saline solution, 250 cc | Office | 2023 | 40 | 657 | $1,084 | $313.21 | 28.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 335 | 941 | $197,610 | $74,194 | 37.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 352 | 402 | $164,670 | $61,323 | 37.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 43 | 1,019 | $247,525 | $55,929 | 22.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 135 | 408 | $114,240 | $39,059 | 34.2% |
| J1335 | Injection, ertapenem sodium, 500 mg | Office | 2022 | 22 | 955 | $96,825 | $14,573 | 15.1% |
| 96374 | Injection of drug or substance into vein | Office | 2022 | 18 | 365 | $67,299 | $11,599 | 17.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 80 | 80 | $31,709 | $10,563 | 33.3% |
| J0878 | Injection, daptomycin, 1 mg | Office | 2022 | 17 | 265,600 | $501,795 | $9,675 | 1.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 25 | 30 | $10,625 | $2,620 | 24.7% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2022 | 16 | 1,781 | $3,845 | $672.71 | 17.5% |
| J7050 | Infusion, normal saline solution, 250 cc | Office | 2022 | 46 | 1,119 | $1,846 | $561.09 | 30.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 283 | 774 | $162,540 | $62,284 | 38.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 103 | 247 | $87,480 | $35,549 | 40.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 200 | 218 | $89,380 | $34,079 | 38.1% |
| 96374 | Injection of drug or substance into a vein for therapy, diagnosis, or prevention | Office | 2021 | 32 | 856 | $157,829 | $28,644 | 18.1% |
About Dr. Thuan Le, M.D
Dr. Thuan Le, M.D is a Infectious Disease healthcare provider based in Murrieta, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1396842704.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Thuan Le, M.D has received a total of $196,559 in payments from pharmaceutical and medical device companies, with $3,496 received in 2024. These payments were reported across 1,012 transactions from 41 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($104,738).
As a Medicare-enrolled provider, Le has provided services to 4,280 Medicare beneficiaries, totaling 1,474,872 services with total Medicare billing of $1.2M. Data is available for 4 years (2020–2023), covering 49 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Murrieta, CA
- Active Since 09/20/2006
- Last Updated 09/05/2014
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1396842704
Products in Payments
- ZERBAXA (Drug) $29,127
- Kimyrsa (Drug) $24,770
- ORBACTIV (Drug) $18,912
- VIBATIV (Drug) $16,734
- Vabomere (Drug) $10,911
- REBYOTA (Biological) $10,275
- Qutenza (Drug) $9,407
- VABOMERE (Drug) $8,768
- CRESEMBA (Drug) $7,172
- ZEMDRI (PLAZOMICIN) (Drug) $7,099
- Baxdela (Drug) $6,735
- Cresemba (Drug) $6,708
- Vibativ (Drug) $5,923
- Arikayce (Drug) $4,618
- Orbactiv (Drug) $4,496
- RECARBRIO (Drug) $2,857
- CABENUVA (Biological) $1,437
- NUZYRA (Drug) $1,192
- DOVATO (Drug) $1,161
- XERAVA (Drug) $779.80
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.